• share
• favorite_border

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.

• share
• favorite_border

Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers.

• share
• favorite_border

Dana-Farber Cancer Institute has implemented an artificial intelligence (AI) application intended for general use in a medical center or hospital.

• share
• favorite_border

In a survey of more than 200 U.S. oncologists, vast majority indicate that oncologists should be able to explain how AI works to their patients. Respondents say AI developers, more than oncologists or hospitals, have responsibility for legal issues arising from AI use in cancer care.

• share
• favorite_border

Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

• share
• favorite_border

The American Society of Clinical Oncology (ASCO) recognized Janet L. Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, as a recipient of an ASCO Special Award, the Society’s highest honor.

• share
• favorite_border

For the fifth straight time, the American Nurses Credentialing Center (ANCC) has awarded Magnet® status to Dana-Farber Cancer Institute, recognizing excellence in nursing practice and patient care.

• share
• favorite_border

Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).

• share
• favorite_border

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute. In this new role, he will lead Dana-Farber's institutional research strategy with an initial focus on therapeutic discovery work.

• share
• favorite_border

In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.

• share
• favorite_border

Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the third Transatlantic Exchange in Oncology Conference will address: Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.The meeting, supported by L’Institut Servier, will be held in-person (witha virtual attendance option) on April 12, 2024, at the Revere Hotel Boston Common and livestreamed virtually on Medscape’s platform.

• share
• favorite_border

The findings out of Dana-Farber Cancer Institute highlight that the mechanisms of immune modulation are different in patients treated with immunotherapy and anti-angiogenic combinations. The results also point to the role of tumor biology in the diversity and actions of tumor-infiltrating immune cells brought into action by these treatments. The findings might be important for predicting or understanding treatment outcomes in advanced kidney cancer.

• share
• favorite_border

Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.

• share
• favorite_border

Researchers at Dana-Farber Cancer Institute and the University of Trento, Italy, have developed a blood test, described in Cancer Discovery, that can reliably detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate cancer-adenocarcinoma.

• share
• favorite_border

• Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters

• share
• favorite_border

George Demetri, MD, director of the Sarcoma Center at Dana-Farber Cancer Institute, is being awarded the prestigious J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA).

• share
• favorite_border

Patients with advanced prostate cancer with tumors harboring RB1 gene loss or neuroendocrine features often have a poor prognosis and limited treatment options.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.

• share
• favorite_border

Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors

• share
• favorite_border

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

• share
• favorite_border

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain.

• share
• favorite_border

The Kraft Family Blood Donor Center, which provides lifesaving blood products to patients at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, announced today that it has finished implementing a more inclusive blood donation process, in alignment with updated guidelines issued by the U.S. Food and Drug Administration (FDA) that will allow many gay and bisexual men to donate blood and platelets.

• share
• favorite_border

Do you know your risk for breast and ovarian cancer? How about steps you can take to reduce your chances of developing cancer or what a family history might mean for your risk of the disease?

• share
• favorite_border

Bradley Bernstein, MD, PhD, Chair of Cancer Biology at Dana-Farber Cancer Institute, has been elected to the National Academy of Medicine (NAM).

• share
• favorite_border

IDRs comprise a large percentage of the human proteome and are particularly important for nuclear proteins that govern our genomic architecture and gene expression.

• share
• favorite_border

• share
• favorite_border

The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers William Freed-Pastor, MD, PhD, and Julien Dilly, MS, research grants of $250,000 and $150,000, respectively over a 2-year period, to support their crucial work in the field of pancreatic cancer research.